[Genetic testing for predicting treatment response in major depressive disorders]
Martínez-Romero B, Llanos-Méndez A
Record ID 32013000861
Authors' objectives: Genetic testing for predicting response and / or tolerance to treatment with antidepressant are based on the identification of genes associated with cytochrome P450, mainly CYP2D6 and CYP2C19, which allows to classify patients according to their ability to metabolize (poor, intermediate, extensive and ultrarapid). Alpha A systematic review was conducted in order to assess the effectiveness of genetic tests to predict response to antidepressant treatment and the occurrence of adverse events.
Authors' recommendations: The selected documents were a Elath technology report, two systematic reviews and seven original articles (three cohort studies and four case-control studies) The main methodological limitation was the high risk selection bias. No association between metabolizer profiles and treatment response except in of the studies, in which patients classified as intermediate metabolizers had a remission faster than the rest. In terms of tolerance, only one of the three studies that offered this outcome found an increased risk of a change in treatment among users of tricyclic antidepressants (OR = 5.77, 95% CI 1.59 to 21.03, p = 0.01). This risk was higher in poor metabolizers than in extensive. However, it was found that the dose of drug required was higher in poor metabolizers.
Project Status: Completed
URL for project: https://www.aetsa.org/publicacion/test-geneticos-para-la-prediccion-de-la-respuesta-al-tratamiento-en-la-depresion-mayor/
Year Published: 2013
URL for published report: https://www.aetsa.org/download/publicaciones/antiguas/AETSA_2012_17_1_Tests_Gen_Psiq.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Depressive Disorder, Major
- Treatment Outcome
Organisation Name: Andalusian Health Technology Assessment Area
Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.